3
WILMINGTON, Del.– AstraZeneca cutting ~600 US jobs as part of a $1.5B cost-saving overhaul; pharma restructuring in motion.
The cuts are concentrated in specific therapeutic areas. The layoffs in respiratory and immunology signal meaningful restructuring pressure at one of the world’s largest pharma companies.
The decision comes as large pharmaceutical companies look for efficiencies amid pricing pressure and rising development costs in the U.S. market.
